Phio Pharmaceuticals (United States)
Phio Pharmaceuticals Corporation is a US clinical stage biotechnology company developing its INTASYL siRNA in immuno-oncology. Formerly known as RXi Pharmaceuticals, the company's name was changed to Phio Pharmaceuticals in 2018. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Phio Pharmaceuticals (United States), United States, covering academic research published from 2009 to 2025. Read More.
Open Access Percentage
57%
Total
Publications
77
Total Open
Publications
44
Total
Citations
1K
Open Access
Percentage
57%
Total
Publications
77
Total Open
Publications
44
Total
Citations
1K
Breakdown
Publisher Open
32%
Both
21%
Other Platform Open
4%
Closed
43%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 17%
7
Hybrid 20%
8
No Guarantees 63%
26
Other Platform Open
Institution 47%
9
Domain 47%
9
Preprint 11%
2
Other Internet 5%
1
Public 0%
0
Other Platform Locations
Name | Platform Type | Publications |
|---|---|---|
PubMed Central | Domain | 9 |
doaj.org OAI-PMH Repository | Institution | 8 |
Research Square | Preprint | 2 |
Unknown Repository | Other Internet | 1 |
London Metropolitan University | Institution | 1 |